The Au079 Target Specific Platform
Enabling the destruction of tumor vasculature.
Built around a gold nanoparticles, Au079 is designed to allow cancer therapies to more efficiently target the tumor.
By treating solid tumors with immune modulating cytokines in previously impossible-to-dose drug combinations, we are able to activate an immune response and disrupt the vasculature of the tumor.
Formulation
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec purus tortor, venenatis id nisi non, dignissim egestas ligula. Praesent scelerisque, libero sed lobortis efficitur, mauris nunc maximus purus, id faucibus mi elit vel tellus. Nullam nec vehicula odio, ut rhoncus nulla. Praesent scelerisque ex quis ligula ultricies, quis vulputate nunc volutpat.
Clinical highlights
Exceeded safety thresholds: The formulation has demonstrated the ability to surpass the Maximally Tolerated Dose (MTD) of TNF without dose-limiting toxicities typically associated with TNF, such as hypotension and hepatotoxicity.
Enhanced TNF exposure: Increases systemic exposure to TNF by up to 40- fold compared to conventional formulations.
Innovating on the Au079 Platform
Building on the Au079 platform: Advancements in clinical formulation are further refining the balance between potency and safety.
Increased TNF payload: Novel formulations of Au079 have been developed to boost TNF particle content by 2-3 times without compromising the stealth properties of the nanoparticles.
Optimized PEG-THIOL composition: Modifications in the composition of PEG-THIOL have unlocked new possibilities:
- Variable PEG-THIOL chain lengths: Using a combination of “shorter” or “taller” PEG-THIOL molecules allows for more efficient TNF binding and accessibility.
- Introduction of PolyPEG: This approach offers the potential to unmask TNF molecules otherwise shielded by the 20 kDa PEG-THIOL, enhancing therapeutic engagement with tumor targets.
By leveraging these innovations, the platform continues to push the boundaries of nanotechnology-based cancer therapy, enhancing the effectiveness of TNF while maintaining a favorable safety profile.
